Patients after nRCT showed a trend towards a more frequent change in the treatment modality to stent therapy (nCT n = 4 (30.77%) vs. nRCT n = 7 (53.85%) p = 0.518); this was, however, not statistically significant ( Figure 1 ).
Up to 3 nM, DHT stimulation showed a trend to decrease gene expression levels of FGF7 (p = 0.52), IGF1 (p = 0.85) and WNT5a (p = 0.08) [ Figure 1b ].
Under the pattern-mixture model sensitivity analysis, the effect of the TM upon relative missed days rate showed a trend but was even less pronounced (0.67 per month in TM vs 0.58 in UC, RMD 30=1.24, 95% CI 0.65-2.39; P =.52).
PCOS cases showed a trend of high OR for positive pregnancy (2.22; 95% CI, 0.19–25.72; P =0.52), followed by unexplained infertility, tubal factors, and endometriosis group; the latter was taken as the reference group.
Tumors with Ki-67 ≥30% and/or RS results ≥26 showed a trend toward higher RCB 0 to I rates with chemotherapy (23% vs. 17%; P = 0.52).
The results showed a trend toward reduced LVESVI in the experimental group compared to that in the control group (RR = 0.41, 95% CI −0.85 to 1.67; p = 0.52).
Nighttime-associated elevation in SVR showed a trend ( p = 0.53) to be higher in people with obesity (248.5 ± 166.6 dynes/sec/cm −5 , 17.9 ± 11.1%) than in men (182.3 ± 113.4 dynes/sec/cm −5 , 14.5 ± 8.9%).
We analyzed the final VA of liver abscess and UTI cases seperately: cases of liver abscess demonstrated a significantly worse outcomes (initial VA logMAR:final VA logMAR = 1.51 ± 0.86:1.88 ± 1.23, p = 0.02, Wilcoxon test), wherars cases of UTI showed a trend of better outcomes (initial VA logMAR:final VA logMAR = 1.71 ± 0.95:1.36 ± 1.19, p = 0.53, Wilcoxon test).
Although the I-CRT-I group showed a trend toward reduced progression risk (HR = 0.91, 95% CI 0.68–1.22; p =0.530), no statistically significant improvement in PFS was observed compared with the CRT-I group.
While the peritoneal group showed a trend toward lower postoperative complication rates (3% vs. 8%), this difference did not reach statistical significance ( p = 0.53).
CKD patients with PD showed a trend of longer dialysis vintage compared to those with HD (39.85 ± 39.44 month vs. 35.35 ± 32.33 month, p = 0.532).
Regression estimates showed a trend toward a prolonged time to recovery with LDN (aHR 0.89; 95% CI: 0.63-1.28, p=0.54) and a trend toward a decrease in the day of disease recovery and LOE with colchicine (aHR 1.32; 95% CI: 0.91-1.82, p=0.16).
A subgroup analysis of patients in the bed rest group comparing mean time to recovery between those who underwent incision biopsy versus no biopsy showed a trend toward faster recovery in patients without biopsy (49 days versus 40 days, P =0.54).
After pIC-MSC co-culture, total leukocytes showed a trend in reduction of apoptosis in blood from severe COVID-19 patients (p = 0.55 for COVID-19 versus COVID-19/Ctrl-MSC, p = 0.093 for COVID-19 versus COVID-19/pIC-MSC) ( Figure 5 F).
An interim analysis showed a trend of improvement on disease-free survival (DFS) and overall survival (OS) in arm B with hazard ratios (HR) of 1.25 (95% CI = 0.60–2.60, p = 0.55) and 1.43 (95% CI = 0.64–3.20, p = 0.38) for DFS and OS, respectively.
In multivariate survival analysis, we found that TLG was an independent prognostic factor for OS (HR=3.22, 95% CI%:1.080-9.582, p=0.036), and TMTV showed a trend as an independent predictor of OS (HR=7.19, 95% CI%:0.957-54.00, p=0.55).
Although multimeric vaccines showed a trend toward higher neutralization titers, this difference was not statistically significant (Wilcoxon rank-sum test, p = 0.55).
Relapse (20.1% (10.6–29.7) versus 35.2% (24.3–46.1), P = 0.058) showed a trend toward lower incidence in the >9 Gy group, while NRM (12.6% (3.9–21.4) versus 14.4% (7.1–21.6), P = 0.551), GRFS 39.3% (29.0–53.3) versus 35.8% (26.5–48.4), P = 0.458), aGVHD 38.3% (27.0–49.6) versus 22.7% (14.1–31.3), P = 0.030) and cGVHD outcomes were comparable.
However, all the enrolled patients experiencing clinically bleeding showed a trend toward a hypocoaguable state on TEG at T 0 , with longer R (median 9.7 vs 8.1 min; p=0.56) and K (median 3.1 vs 2.3 min; p= 0.65) compared to their non-bleeding counterparts.
Presence of hypercalcemia showed a trend to positively influence end-of-follow-up GFR (+19 ± 33 ml/min/1.73 m 2 , p = 0.56).
2c ) .When we excluded the good prognosis subgroup (Q4 PFS) from the survival analysis, the SENS signature showed a trend in separating the PFS curves of “SENS+ without the 75 th percentile” (SENS+ w/o 75 th ) and SENS─ patients (mPFS values of 9.30 and 6.30 months, respectively; p = 0.560) (Fig. 2c ).
Although CFU counts showed a trend toward recovery with increasing delay, one-way ANOVA detected no significant differences among groups ( p = 0.565).
OI patients showed a trend towards higher mean right-leg fat thickness than the control group (0.56±0.33 cm vs. 0.50±0.18 cm, p = 0.568).
However, only one cluster showed a trend of significance ( p = 0.57) and the Talairach coordinates for the cluster was (X = −31.5, Y = −2.9, Z = 16.7).
PDR blood sample analysis as compared to controls showed a trend for increased expression of VEGFA by 1.2-fold (PDR = 0.88, control = 0.74, p = 0.57), whereas the other examined genes showed a trend of reduced expression; HIF2A decreased by 0.50-fold (PDR = 0.38, control = 0.75, p = 0.07), PAI by 0.51-fold (PDR = 0.35, control = 0.69, p = 0.09), TIE-1 by 0.79-fold (PDR = 0.79, control = 1.00, p = 0.54), TIE-2 by 0.70-fold (PDR = 0.58, control = 0.82, p = 0.34), and ANGPT2 by 0.45-fold (PDR = 0.51, control = 1.15, p = 0.11).